Daniel Bach

Also in Washington, efforts to ban popular drones made in China have finally paid off.

The Federal Communications Commission announced a ban on the tech yesterday.

It was prompted by a White House-led group that informed the commission the drones posed unacceptable risks.

The ban covers all drones and critical components made in a foreign country, including from major Chinese manufacturers like DJI and Hotel Robotics.

The move has been met with uproar from many of the nearly half a million American commercial drone pilots, many of whom say that American drones just can't compete.

DJI said it was disappointed with the FCC's decision and reiterated the security of their products.

Othell didn't respond to a request for comment.

U.S.

regulators have approved the first GLP-1 weight loss pill, a tablet formulation of Novo Nordisk's Ozempic and Wegovy.

The drugmaker said the pills could be available in the U.S.

in early January and will cost $149 a month for the starting dose.

The move into pill format is expected to broaden the use of the drug.

So far, the obesity market has been dominated by weekly shots, which put many people off the idea of taking it, either due to cost, insurance coverage, or a fear of needles.

Well, as we get closer to 2026, talk of midterm elections is only growing louder in Washington.

And there will be a lot of open races.

According to Ballotpedia, 52 lawmakers will not be seeking re-election.

Our Washington coverage chief, Damian Paletta, says that number could soon surpass the 54 who retired in 2018, which was the most in any election cycle going back to 2012.

In markets, investors are looking ahead to the delayed third quarter U.S.

GDP data coming at 8.30 a.m.

Eastern.